Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alastair Thompson

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
Scientific Reports|July 11, 2024
Multiparametric MRI-based radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancerRania M Mohamed, Bikash Panthi, Beatriz E Adrada, et al.
Frontiers in Oncology|November 9, 2023
Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancerBikash Panthi, Rania M Mohamed, Beatriz E Adrada, et al.
The Lancet. Oncology|November 22, 2017
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trialMarco Colleoni, Weixiu Luo, Per Karlsson, et al.
NPJ Breast Cancer|November 20, 2025
Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancerMary S Guirguis, Beatriz E Adrada, Clinton Yam, et al.
Cancers|March 28, 2025
Deep Learning Models Based on Pretreatment MRI and Clinicopathological Data to Predict Responses to Neoadjuvant Systemic Therapy in Triple-Negative Breast CancerZhan Xu, Zijian Zhou, Jong Bum Son, et al.
Breast Cancer Research : BCR|January 31, 2024
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancerFilipa Lynce, Laura E Stevens, Zheqi Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2020
Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE TrialElena Guerini-Rocco, Kathryn P Gray, Caterina Fumagalli, et al.
Cancers|October 14, 2023
Deep Learning for Fully Automatic Tumor Segmentation on Serially Acquired Dynamic Contrast-Enhanced MRI Images of Triple-Negative Breast CancerZhan Xu, David E Rauch, Rania M Mohamed, et al.
Cancers|February 25, 2023
Assessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRIBikash Panthi, Beatriz E Adrada, Rosalind P Candelaria, et al.
Biorxiv : the Preprint Server for Biology|May 10, 2023
A spatially resolved single cell genomic atlas of the adult human breastTapsi Kumar, Kevin Nee, Runmin Wei, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Scientific Reports|July 11, 2024
Multiparametric MRI-based radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancerRania M Mohamed, Bikash Panthi, Beatriz E Adrada, et al.
Frontiers in Oncology|November 9, 2023
Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancerBikash Panthi, Rania M Mohamed, Beatriz E Adrada, et al.
The Lancet. Oncology|November 22, 2017
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trialMarco Colleoni, Weixiu Luo, Per Karlsson, et al.
NPJ Breast Cancer|November 20, 2025
Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancerMary S Guirguis, Beatriz E Adrada, Clinton Yam, et al.
Cancers|March 28, 2025
Deep Learning Models Based on Pretreatment MRI and Clinicopathological Data to Predict Responses to Neoadjuvant Systemic Therapy in Triple-Negative Breast CancerZhan Xu, Zijian Zhou, Jong Bum Son, et al.
Breast Cancer Research : BCR|January 31, 2024
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancerFilipa Lynce, Laura E Stevens, Zheqi Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2020
Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE TrialElena Guerini-Rocco, Kathryn P Gray, Caterina Fumagalli, et al.
Cancers|October 14, 2023
Deep Learning for Fully Automatic Tumor Segmentation on Serially Acquired Dynamic Contrast-Enhanced MRI Images of Triple-Negative Breast CancerZhan Xu, David E Rauch, Rania M Mohamed, et al.
Cancers|February 25, 2023
Assessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRIBikash Panthi, Beatriz E Adrada, Rosalind P Candelaria, et al.
Biorxiv : the Preprint Server for Biology|May 10, 2023
A spatially resolved single cell genomic atlas of the adult human breastTapsi Kumar, Kevin Nee, Runmin Wei, et al.
Pageof 10